Ann: Positive first animal data for Cancer Program, page-2

Great presentation yesterday by Prof Trent Munro and he has then followed through today with a great result.
Microba is in pole position to develop a microbiome based therapeutic for patients receiving immune checkpoint inhibitor therapy across a range of cancers. Only 30% of cancer patients respond to cancer drugs but combined with a microbiome based therapeutic it can increase that response rate substantially.

I can see Microba partnering up quickly with big pharma.

A US$30 bil opportuniity for Microba with a greater than 15% CAGR.